MORRISVILLE, N.C., June 25, 2013 (GLOBE NEWSWIRE) -- nContact, Inc., the leading innovator in epicardial ablation devices and techniques, announced today the receipt of two new issued U.S. patents that further solidifies its innovative multidisciplinary approach in cardiac ablation. The newly issued patents expand on and protect the technologies and techniques that enable the creation of more complete and comprehensive lesions by realizing the benefits of a combined epicardial and endocardial ablation approach.
"The combined epicardial-endocardial approach has enhanced our ablation results primarily because the combination represents a more comprehensive procedure," said James McKinnie, MD, Director Arrhythmia Center East Jefferson General Hospital and West Jefferson Medical Center, Metairie, LA. "It has allowed our institution to meet the needs of patients who could not be treated effectively, historically by single disciplinary ablation approaches. nContact's proprietary ablation tool design, transdiaphragmatic access, and epicardial-endocardial approach have transformed our practice."
The multidisciplinary epicardial-endocardial approach is performed as a single procedure in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2 cm incision in the abdomen, with no need for chest incisions or ports. The endocardial lesions created by an electrophysiologist help confirm lesion set completeness through specialized EP diagnostics, which also predict patient outcomes.
"The issuance of these patents represents an ongoing corporate effort to protect our technology and 'Epi-Endo' approach through an expansive portfolio of device and methodology patents," said John Funkhouser, President of nContact. "We continue to develop best practices to standardize our combined approach for cardiac arrhythmia ablation."
About nContact, Inc.
nContact's mission is to transform the underserved arrhythmia market through the advancement of less invasive, more efficacious ablation alternatives for cardiac arrhythmias. The Company's lead technologies, EPi-Sense® and Numeris® Coagulation Systems with VisiTrax,® have CE Mark approval in Europe for the coagulation of cardiac tissue in the treatment of atrial fibrillation and atrial flutter. The EPi-Sense and Numeris Coagulation Systems with VisiTrax are indicated for endoscopic coagulation of cardiac tissue in the U.S. nContact was founded in 2005 and is headquartered in Morrisville, North Carolina, USA.